Tramadol hydrochloride (Ultram, Tramal others below) is a centrally acting opioid analgesic, used in treating moderate to severe pain. The drug has a wide range of applications, ultram withdrawals, including treatment for restless leg syndrome and fibromyalgia. It was developed by the pharmaceutical company Grünenthal GmbH in the late 1970s.

Tramadol possesses weak agonist actions at the μ-opioid receptor, releases serotonin, and inhibits the reuptake of norepinephrine.

Tramadol is a synthetic analog of the phenanthrene alkaloid codeine and, as such, is an opioidand also a prodrug (codeine is metabolized to morphine, tramadol is converted to O-desmethyltramadol), by tramadol. Opioids are chemical compounds which act upon one or more of the human opiate receptors. The euphoria and respiratory depression are mainly caused by the μ1and μ2 receptors; the addictive nature of the drug is due to these effects as well as its serotonergic/noradrenergic effects. The opioid agonistic effect of tramadol and its major metabolite(s) are almost exclusively mediated by the substance's action at the μ-opioid receptor. This characteristic distinguishes tramadol from many other substances (including morphine) of the opioid drug class, which generally do not possess tramadol's degree of subtype selectivity.

Tramadol is used similarly to codeine, to treat moderate to moderately severe pain and most types of neuralgia, including trigeminal neuralgia. Tramadol is somewhat pharmacologically similar to levorphanol (albeit with much lower μ-agonism), tramadol not for sale, as both opioids are also NMDA-antagonists which also have SNRI activity (other such opioids to do the same aredextropropoxyphene (Darvon) & M1-like molecule tapentadol (Nucynta, a new synthetic atypical opioid made to mimic the agonistic properties of tramadol's metabolite, by tramadol, M1(O-Desmethyltramadol), ultram withdrawals. Tramadol is also molecularly similar to Effexor (Venlafaxine) and has similar SNRI effects, with antinociceptive effects also observed. It has been suggested that tramadol could be effective for alleviating symptoms of depression, anxiety, and phobias because of its action on the noradrenergic and serotonergic systems, such as its "atypical" opioid ver, health professionals have not endorsed its use for these disorders, claiming it may be used as a unique treatment (only when other treatments failed), and must be used under the control of a psychiatrist.

In May 2009, ultram withdrawals, the United States Food and Drug Administration issued a Warning Letter to Johnson & Johnson, alleging that a promotional website commissioned by the manufacturer had "overstated the efficacy" of the drug, and "minimized the serious risks". The company which produced it, the German pharmaceutical company Grünenthal GmbH, were the ones alleged to be guilty of "minimizing" the addictive nature and proposed efficacy of the drug, although it showed little abuse liability in preliminary tests. The 2010 Physicians Desk Reference contains several warnings from the manufacturer, which were not present in prior years. The warnings include more compelling language regarding the addictive potential of tramadol, the possibility of difficulty breathing while on the medication, a new list of more serious side effects, and a notice that tramadol is not to be used in place of opiate medications for addicts. Tramadol is also not to be used in efforts to wean addict patients from opiate drugs, nor to be used to manage long-term opiate addiction.

Tramadol is usually marketed as the hydrochloride salt (tramadol hydrochloride); the tartrate is seen on rare occasions, and rarely (in the US at least) tramadol is available for both injection (intravenous and/or intramuscular) and oral administration. The most well known dosing unit is the 50 mg generic tablet made by several manufacturers. It is also commonly available in conjunction with APAP (Paracetamol, Acetaminophen) as Ultracet, in the form of a smaller dose of �mg tramadol and 325 mg of APAP. The solutions suitable for injection are used in patient-controlled analgesia pumps under some circumstances, either as the sole agent or along with another agent such as morphine.

Tramadol comes in many forms, ultram withdrawals, including:

Tramadol has been experimentally used in the form of an ingredient in multi-agent topical gels, creams, mixing ambien and xanax and lexapro, and solutions for nerve pain, rectal foam, concentrated retention enema, ultram withdrawals, and a skin plaster (transdermal patch) quite similar to those used with lidocaine.

Tramadol has a characteristic and unpleasant taste which is mildly bitter but much less so than morphine and codeine. Oral and sublingual drops and liquid preparations come with and without added flavoring. Its relative effectiveness via transmucosal routes (i.e. sublingual, ultram withdrawals, buccal, tramadol and headache treatment, rectal) is similar to that of codeine, ultram withdrawals, and, like codeine, it is also metabolized in the liver to stronger metabolites (see below).

The maximum dosage per day is 400 mg for oral use and 600 mg for parenteral use. Certain manufacturers or formulations have lower maximum doses. For example, Ultracet (37.5 mg/325 mg tramadol/APAP tablets) is capped at 8 tablets per day (300 mg/day) due to its acetaminophen content. Ultram ER is available in 100, 200, ultram withdrawals, and 300 mg/day doses and is explicitly capped at 300 mg/day as well.

Patients taking SSRIs (Prozac, Zoloft, etc.), SNRIs (Effexor, etc.), TCAs, MAOIs, or other strong opioids (oxycodone, methadone, by tramadol, fentanyl, ultram withdrawals, morphine), as well as the elderly (> 75 years old), pediatric (< 18 years old), mixing ambien and xanax and lexapro, and those with severely reduced renal (kidney) or hepatic (liver) function should consult their doctor regarding adjusted dosing or whether to use Tramadol at all.

Synthetic marijuana consists of smokeable leaves of plants that have been covered in chemicals that mimic THC, the active ingredient in actual marijuana. Considered to be one of the newest designer drugs, fake pot makers market the substances as “herbal”. However, little credible evidence exists to back up the assertion. Popular among young people, fake pot is typically sold in drug paraphernalia shops and on the Internet. Fake pot is marketed under the brands Spice, ultram withdrawals, K2, Blaze, Mr. Nice Guy and Red X Dawn and it typically referred to as “incense”, ultram withdrawals. The products also claim to be undetectable during drug tests and retail for even more than real pot.

Law enforcement officials, hospitals and even poison control centers have documented many reports of adverse reactions to the synthetic marijuana, including seizures and hallucinations. Evidence also exists that synthetic marijuana may actually be addictive, ultram withdrawals. The American Association of Poison Control Centers claims to have received over fifteen hundred calls nationwide concerning use of fake pot. A seventeen year old boy recently smoke synthetic marijuana and had to be rushed to the emergency room for muscle contractions, low blood pressure (BP) and a racing heart.

The US Drug Enforcement Agency (DEA) recently initiated an emergency lockdown on fake pot, mixing ambien and xanax and lexapro, focusing on five chemicals use to create the substances, ultram withdrawals. Over the next thirty days, the DEA will try to have the chemicals classified in the same category as illicit drugs such as heroin and cocaine, ultram withdrawals. The emergency action is quickest way the DEA can legally get the products off the shelves. The federal government first became aware of the drugs in the fall of ’08, when a CBP (Customs & Border Protection) officer evaluated an incoming shipment of “Spice”. In early 2010, CBP took possession of over 100 pounds of two of the five target chemicals.

Although the DEA is just now taking action, tramadol and headache treatment, over fifteen states have already taken steps to regulate the chemicals present in fake pot, ultram withdrawals. In a perverse twist, it turns out that the man who invented three of the five chemicals did so as part of a government-sponsored research project two decades ago; even he admits the substances are dangerous and can result in overdose, addiction or suicide. More importantly, the effects of synthetic pot on the human body have never even been studied.

Real marijuana typically results in sleepiness and, occasionally, by tramadol, paranoia. Users of synthetic pot, tramadol and headache treatment, however, ultram withdrawals, report dizziness, nausea, agitation, fast heartbeat, and hallucinations. Other users have fallen into comas or have heart arrhythmias. One team reported having hallucinated that he was standing at the edge of a cliff, by tramadol, getting ready to jump. It turns out that he was actually standing at the edge of a curb and dove off it, injuring his mouth and chin, ultram withdrawals. In addition, he experienced shortness of breath and seizure-like symptoms for about 6 hours.

After the thirty days is up, the DEA will likely ban fake pot for one year. A ban on fake pot means that anyone found to possess or to have sold the products or chemicals within the product will be guilty of a crime.